Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immune Checkpoint Blockade for Kidney Transplant Recipients With Advanced Cancers
NCT03816332Phase 1Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Nov 2019
- Primary completion
- Oct 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nivolumab and ipilimumab in melanoma, basal cell carcinoma (BCC), Merkel cell carcinoma (MCC) and 2 more, sponsored by National Cancer Institute. Primary endpoint: Number and Percentage of Outcome Responses (CR, PR, SD without allograft loss) at 16 weeks. Started Nov 2019; status: active, not recruiting.
02
Drugs
nivolumabipilimumab
03
Conditions
melanomabasal cell carcinoma (BCC)Merkel cell carcinoma (MCC)squamous cell carcinoma (SCC)microsatellite instability-high cancer
Beyond the preview
Go deeper on NCT03816332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03816332.